

Simultaneous Multiplex Detection of Sense and Antisense Strands of Therapeutic siRNA using an Ultrasensitive Electrochemiluminescence Assay


Rohini Datta, Timothy J. Break, Seth B. Harkins, Jeff Debad, and Jacob N. Wohlstadter
Meso Scale Discovery, Rockville, Maryland, USA

1 Background

- Small interfering RNA (siRNA) molecules play a key role in gene regulation and therapeutic applications. Currently, there are at least five FDA approved siRNA drugs, with many more in clinical trials, making their precise detection of paramount importance in preclinical research and translational medicine.
- Measuring both strands of duplex siRNA is essential for optimizing efficacy and safety and for addressing safety concerns. Most pharmacokinetic assays for detecting siRNA rely on low-sensitivity formats like LC-MS or singleplex assays of the sense strand (SS) and the antisense strand (AS), in separate wells. Simultaneous detection of both siRNA strands in a single well is challenging, since the strands share a high degree of sequence complementarity, leading to cross-hybridization between capture probes and high false positive signals.
- We present a rapid and efficient approach for multiplex detection of both strands of duplex siRNA using an ultrasensitive electrochemiluminescence (ECL) assay on the Meso Scale Discovery® (MSD) platform. Not only does the method provide reproducible multiplex detection of both strands of duplex siRNA, it does so with femtomolar (fM) sensitivity.
- Lower limits of quantitation (LLOQs) were 798 fM for the SS strand and 546 fM for the AS strand. We also demonstrated the versatility and robustness of this detection strategy in complex biological matrices such as mouse plasma, brain, and liver.

2 MSD® Technology

The Meso Scale Discovery® (MSD) ECL detection technology uses SULFO-TAG™ labels that emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY® and MULTI-SPOT® microplates.



Electrochemiluminescence Technology

- Minimal non-specific background and strong responses to analyte yield high signal-to-background ratios.
- The stimulation mechanism (electricity) is decoupled from the response (light signal), minimizing matrix interference.
- Only labels bound near the electrode surface are excited, enabling non-washed assays.
- Labels are stable, non-radioactive, and directly conjugated to biological molecules.
- Emission at ~620 nm eliminates problems with color quenching.
- Multiple rounds of label excitation and emission enhance light levels and improve sensitivity.
- Carbon electrode surface has 10X greater binding capacity than polystyrene wells.
- Surface coatings can be customized.

N-PLEX® platform:

N-PLEX plates contain up to 10 unique capture oligonucleotides that are bound to their corresponding spot on the electrode surface. Detection of a nucleic acid sequence of interest is accomplished by hybridization of one or more probes with complementary sequence to these capture oligos and the nucleic acid of interest, followed by detection via electrochemiluminescence. Blocking, hybridization, and detection are achieved using MSD proprietary buffers and diluents.

siRNA analyte:

The model therapeutic analyte is a 20-mer duplex siRNA, based on GTI-2040 (Lee *et al.*, Cancer Res, 2003, PMID: 12782585) with the following sequence: antisense strand (AS): 5'-GCCTAAATCGCTCCACCAAG-3' and sense strand (SS): 5'-CTTGGTGAGCGATTAGCC-3'

3 Results – siRNA detection using RNase protection assay

Singleplex detection of SS and AS strands of siRNA:

The RNase protection assay uses chimeric probes specific to either the SS or AS strands to detect siRNA on the N-PLEX platform. Singleplex assays were carried out in separate wells for the SS and AS strands. Chimeric probes contain a 5' DNA sequence complementary to the N-PLEX plate-bound capture oligo followed by an RNA sequence complementary to the siRNA strand of interest (SS/AS), with a biotin at the 3' end for detection via streptavidin (SA) bound to SULFO-TAG label. Once the probe was hybridized to the analyte and the plate, an RNase cocktail was added to degrade any single stranded RNA. Any RNA in the probe not fully protected by the siRNA strands is degraded, releasing biotin from the DNA portion of the probe, rendering it undetectable.




Table 1.	eLLOD (fM)		
	Matrix	SS Spot 10	AS Spot 1
Buffer		118	48
Plasma		190	72

Figure 1. A calibration curve was generated using duplex siRNA, using capture probes specific to SS or AS strands, which were detected using an RNase protection assay on the N-PLEX platform (see schematic and protocol). Estimated lower limit of detection (eLLOD) for SS and AS in buffer and plasma are in Table 1.

4 Results – Shortened capture probes for multiplex detection




Figure 2. Shortened capture probes were designed for the SS and AS strands of duplex siRNA. Probes were serially shortened from the 3' end by two or more nucleotides. siRNA strands were detected using RNase protection assay on the N-PLEX platform.




Figure 3. Shortened probes, specific to SS or AS strands, enable multiplexing in a single well. Cross-interactions between SS and AS probes are eliminated by RNase digestion, degrading unbound, single stranded RNA sections not protected by shortened probes. Full-length probes cannot be multiplexed as they form strong, RNase-resistant probe-probe interactions, leading to high, false-positive background signals.

Table 2. Singleplex detection of shortened probes.

Avg. ECL Signal at TOC (4000 pM)	Sense strand (SS), Spot 10				Antisense strand (AS), Spot 1			
	SS 16-mer	SS 17-mer	SS 18-mer	SS 20-mer (Full-length)	AS 16-mer	AS 17-mer	AS 18-mer	AS 20-mer (Full-length)
Signal at TOC (4000 pM)	570,119	418,206	465,431	557,374	826,810	121,758	583,980	834,778
Background (0 pM)	204	155	187	168	259	122	207	298
eLLOD (fM)	166	179	386	190	94	854	252	72




Figure 4. Shortened probes enable ultrasensitive detection in singleplex format. eLLODs are in Table 2.

5 Results – Multiplexed detection in a single well

Table 3. Detection Parameters.

Avg. ECL Signal at TOC (4000 pM)	Sense strand (SS), Spot 10			Avg. ECL Signal at TOC (4000 pM)	Antisense strand (AS), Spot 1		
	SS 16-mer	SS 17-mer	SS 18-mer		AS 16-mer	AS 17-mer	AS 18-mer
SS 16-mer	531,407	536,167	407,662	AS 16-mer	690,503	668,581	634,244
AS 16-mer	520,497	492,520	394,881	AS 17-mer	422,074	368,702	414,987
Signal/Background	SS 16-mer	SS 17-mer	SS 18-mer	Signal/Background	SS 16-mer	SS 17-mer	SS 18-mer
AS 16-mer	1622.623	1088.745	675.505	AS 16-mer	1261.329	62.701	106.021
AS 17-mer	573.911	380.325	315.412	AS 17-mer	501.006	97.863	43.621
eLLOD (fM)	SS 16-mer	SS 17-mer	SS 18-mer	eLLOD (fM)	SS 16-mer	SS 17-mer	SS 18-mer
AS 16-mer	151	160	233	AS 16-mer	308	11920	32286
AS 17-mer	181	148	221	AS 17-mer	492	4767	18501




Figure 5. Shortened probes were multiplexed in combinations, in a single well, to simultaneously detect both siRNA strands. The SS 16-mer + AS 16-mer probe combination was chosen for further experiments based on detection criteria in Table 3 (highest signal-to-background ratio, lowest eLLOD).

6 Results – Dilution Linearity in Mouse Plasma




Figure 6. Mouse plasma was diluted 2-, 4-, 8-, and 16-fold in buffer, and siRNA calibrator was spiked into diluted plasma at three concentrations: high quality control (HQC) of 600 pM, medium quality control (MQC) of 60 pM and low quality control (LQC) of 6 pM. An SS 16-mer and AS 16-mer probe mix was used for multiplex detection of SS and AS. The assay shows excellent linearity of dilution throughout the dynamic range.



MESO SCALE DISCOVERY, Meso Scale Diagnostics, MSD, mesoscale.com, www.mesoscale.com, methodicalmind.com, www.methodicalmind.com, DISCOVERY WORKBENCH, InstrumentLink, MESO, MesoSphere, Methodical Mind, MSD GOLD, MULTI-ARRAY, MULTI-SPOT, QuickPlex, ProductLink, SECTOR, SECTOR HTS, SECTOR PR, SULFO-TAG, TeamLink, TrueSensitivity, TURBO-BOOST, TURBO-TAG, N-PLEX, R-PLEX, S-PLEX, T-PLEX, U-PLEX, V-PLEX, MSD (design), MSD (luminescent design), Methodical Mind (head logo), 96 WELL SMALL-SPOT (design), 96 WELL 1-, 4-, 7-, 9-, & 10-SPOT (designs), 384 WELL 1- & 4-SPOT (designs), N-PLEX (design), R-PLEX (design), S-PLEX (design), T-PLEX (design), U-PLEX (design), V-PLEX (design), It's All About U, Spot the Difference, The Biomarker Company, and The Methodical Mind Experience are trademarks and/or service marks owned by or licensed to Meso Scale Diagnostics, LLC. All other trademarks and service marks are the property of their respective owners. ©2024 Meso Scale Diagnostics, LLC. All rights reserved.

7 Results – Spike Recovery in Mouse Plasma




Figure 7. siRNA calibrator was spiked into mouse plasma at three concentrations. An SS 16-mer and AS 16-mer probe mix was used for multiplex detection of SS and AS. The percent recovery fell within acceptable guidelines of 100 ± 20%.

8 Results – Matrix Testing in Mouse Liver and Brain Lysate




Figure 8. Mouse liver and brain tissue (BALB/c strain) were homogenized in N-PLEX lysis buffer using a bead mill homogenizer. Liver and brain are primary target organs for siRNA therapeutics. Tissue lysate was diluted 1:100 in buffer and siRNA calibrator was spiked in at three concentrations. An SS 16-mer and AS 16-mer probe mix was used for multiplex detection of SS and AS. The percent recovery fell within acceptable guidelines of 100 ± 20%.

9 Results – Reproducibility Testing

Table 4. Multiplex assays were run in mouse plasma for 3 consecutive days (2 runs per day), with highly reproducible results.

Run Statistics	SS 16-mer Spot 10							AS 16-mer Spot 1						
	Run 1	Run 2	Run 3	Run 4	Run 5	Run 6	Average Inter-run statistics	Run 1	Run 2	Run 3	Run 4	Run 5	Run 6	Average Inter-run statistics
Hill Slope	1.00	0.99	1.00	0.99	1.00	1.00	1.00	1.00	1.01	1.00	0.99	1.00	1.02	1.00
Signal at TOC (4000 pM)	285,402	296,923	310,085	271,863	277,496	289,589	288,560	467,740	480,602	501,013	442,674	439,904	432,807	460,790
Background ECL Signal	206	257	229	219	224	236	228	441	494	483	464	441	448	462
Intra-run CV (160 pM)	4.2%	4.4%	4.9%	3.4%	5.5%	4.8%	4.5%	7.3	3.8	1.6	5.7	4.0	3.6	4.3
% Recovery	96%	106%	104%	95%	99%	95%	99%	102%	105%	95%	96%	97%	95%	98%
eLLOD (fM)	275	276	292	298	298	255	282	0.171	0.158	0.059	0.172	0.185	0.169	0.152
eLLOQ (fM)	798							546						

10 Conclusions

- By combining multiplexed detection of SS and AS strands of siRNA with ultrasensitive ECL detection, this approach represents a significant advancement in siRNA analysis techniques for pharmacokinetic studies.
- With the observed femtomolar sensitivity, we achieved >1000-fold improvement in detection compared to other technologies like LC-TOF-MS and LC-MS/MS (Ramanathan and Shen, Bioanalysis, 2019, PMID: 31829057; Yuan *et al.*, Molecules, 2023, PMID: 36838605).
- Through enabling detection of both strands of siRNA within a single reaction with unrivaled sensitivity, our approach paves the way for a deeper understanding of siRNA drug metabolism, distribution and elimination, and promises to accelerate the translation of siRNA therapeutics.